APG 1387

Drug Profile

APG 1387

Alternative Names: APG-1387; SM-1387

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Ascentage Pharma
  • Developer Jiangsu Ascentage Pharma; Southern Medical University
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Lymphoma; Solid tumours
  • Preclinical Hepatitis B

Most Recent Events

  • 08 Jan 2018 Preclinical trials in Hepatitis B in China (Parenteral) before January 2018
  • 08 Jan 2018 The China Food and Drug Administration accepts IND application for Hepatitis B
  • 08 Jan 2018 Ascentage Pharma completes phase I dose-escalation studies in Cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top